Adverse event1 (SOC/PT), n2 (%) | Treatment group | ||||||||
---|---|---|---|---|---|---|---|---|---|
256 μg mRNA | 640 μg mRNA | 1280 μg mRNA | Total N = 44 | Total N = 44 | |||||
N = 3 | N = 3 | N = 38 | |||||||
Grade 1/2 | Grade ≥3 | Grade 1/2 | Grade ≥3 | Grade 1/2 | Grade ≥3 | Grade 1/2 | Grade ≥3 | All Grades | |
Total patients with related AEs | 2 (67) | 1 (33) | 2 (67) | 1 (33) | 30 (79) | 3 (8) | 34 (77) | 5 (11) | 39 (89) |
General disorders and administration site reactions | 2 (67) | 1 (33) | 3 (100) | 0 | 32 (84) | 0 | 37 (84) | 1 (2)*1 | 38 (86) |
Injection site erythema | 2 (67) | 0 | 2 (67) | 0 | 23 (61) | 0 | 27 (61) | 0 | 27 (61) |
Injection site reaction | 2 (67) | 0 | 1 (33) | 0 | 18 (47) | 0 | 21 (48) | 0 | 21 (48) |
Fatigue | 2 (67) | 0 | 0 | 0 | 6 (16) | 0 | 8 (18) | 0 | 8 (18) |
Pyrexia | 0 | 0 | 1 (33) | 0 | 6 (16) | 0 | 7 (16) | 0 | 7 (16) |
Chills | 1 (33) | 0 | 0 | 0 | 4 (11) | 0 | 5 (11) | 0 | 5 (11) |
Influenza-like symptoms | 0 | 0 | 0 | 0 | 5 (13) | 0 | 5 (11) | 0 | 5 (11) |
Musculoskeletal and connective tissue disorders3 | 1 (33) | 0 | 0 | 0 | 5 (13) | 1 (3) | 6 (14) | 1 (2) *2 | 7 (16) |
Nervous system disorders4 | 1 (33) | 0 | 1 (33) | 0 | 4 (11) | 0 | 6 (14) | 0 | 6 (14) |
Renal and urinary disorders5 | 0 | 0 | 0 | 1 (33) | 3 (8) | 2 (5) | 3 (7) | 3 (7)*3 | 6 (14) |
Skin and subcutaneous disorders6 | 0 | 0 | 0 | 0 | 6 (16) | 0 | 6 (14) | 0 | 6 (14) |
Gastrointestinal disorders7 | 1 (33) | 0 | 0 | 0 | 3 (8) | 1 (3) | 4 (9) | 1 (2)*4 | 5 (11) |